Skip to main content
Clinical Orthopaedics and Related Research logoLink to Clinical Orthopaedics and Related Research
. 2011 Aug 24;470(4):1065–1072. doi: 10.1007/s11999-011-2026-4

Measuring the Value of Total Hip and Knee Arthroplasty: Considering Costs Over the Continuum of Care

Deborah A Marshall 1,2,3, Tracy Wasylak 4, Hoa Khong 2, Robyn D Parker 1,2, Peter D Faris 1,2,4, Cy Frank 1,2,3,
PMCID: PMC3293965  PMID: 21863395

Abstract

Background

Controlling escalating costs of hip (THA) and knee arthroplasty (TKA) without compromising quality of care has created the need for innovative system reorganization to inform sustainable solutions.

Questions/purposes

The purpose of this study was to inform estimates of the value of THA and TKA by determining: (1) the data sources data required to obtain costs across the care continuum; (2) the data required for different analytical perspectives; and (3) the relative costs across the continuum of care.

Methods

Within the context of a pragmatic randomized controlled trial comparing alternative care pathways, we captured healthcare resource use: (1) 12 months before surgery; (2) inpatient; (3) acute recovery; and (4) long-term recovery 3 and 12 months postsurgery. We established a standardized costing model to reflect both the healthcare payer and patient perspectives.

Results

Multiple data sources from regional health authorities, administrative databases, and patient questionnaire were required to estimate costs across the care continuum. Inpatient and acute care costs were approximately 60% of the total with the remaining 40% incurred 12 months presurgery and 12 months postsurgery. Regional health authorities bear close to 60%, and patient costs are approximately 30% of the mean total costs, most of which were incurred after the acute inpatient stay.

Conclusions

To fully understand the value of an orthopaedic intervention such as THA and TKA, a broader perspective than one limited to the payer should be considered using a standardized measurement framework over a relevant time horizon and from multiple viewpoints to reflect the substantial patient burden and support sustainable improvement over the care continuum.

Level of Evidence

Level III, economic and decision analyses study. See Guidelines for Authors for a complete description of levels of evidence.

Introduction

Concerns about rising healthcare expenditures have fueled the increased interest in economic evaluation in decision-making processes. Economic evaluation measures the value of medical interventions, considering both outcomes and costs to drive improvements in health care [7]. The demand for total joint arthroplasty (TJA) of the hip (THA) and knee (TKA) for end-stage osteoarthritis is growing exponentially, but its delivery is not yet optimized. Controlling the escalating costs of medical interventions without compromising the quality of care has created the need for innovative system reorganization to help inform sustainable solutions.

In 2003, the Alberta Orthopaedic Society and the Alberta Bone Joint Health Institute undertook an initial comprehensive analysis of the variability in practice patterns and designed a provincial clinical pathway for THA and TKA in Alberta. The goal was to reduce lengthy waiting times for consultation and surgery and to improve care for patients across the full continuum of care from patient referral to an orthopaedic surgeon through surgery, recovery, and rehabilitation. The project involved a partnership of the provincial government agency that funds healthcare (Alberta Health and Wellness), regional healthcare authorities (RHAs), and decision-makers: orthopaedic surgeons, general practitioners, other healthcare physicians, and allied health professionals. This effort resulted in a new evidence-based clinical pathway (NCP) for THAs and TKAs focused on the quality, coordination, and efficiency of care.

In the Alberta Hip and Knee Replacement Project (HKRP) pilot study [9], we found the expected major effects of the surgery and further small but statistically significant benefits using an explicit measurement framework. Our findings suggested the evidence-informed clinical pathway improved access to care and health-related quality of life of patients undergoing hip and knee arthroplasty in routine clinical practice for up to 12 months postoperatively [1].

Furthermore, in reference to our earlier article, we determined healthcare resource use over the continuum of care 12 months before and 12 months postsurgery to estimate (1) the proportion of costs borne by the regional health authority; (2) the proportion of costs generated by acute care versus longer-term care; and (3) the proportion of costs borne by the payer versus patient.

Methods

The NCP was assessed against the conventional method of service delivery or standard of care (SOC) in a pragmatic randomized controlled trial conducted in three of the nine RHAs in Alberta, representing 80% of THAs and TKAs performed in Alberta. We invited 4985 patients who were indicated for THA or TKA to participate between April 2005 and May 2006, of which 3434 consented and were randomized to the NCP or SOC. We developed outcome measures using the Alberta Quality Matrix for Health (AQMH) framework to define the six dimensions of quality care: acceptability, accessibility, appropriateness, effectiveness, efficiency, and safety [12]. The AQMH is a framework that offers a common language, understanding, and approach to healthcare quality. As the primary effectiveness outcome, we compared improvement in WOMAC score [2] at 12 months postsurgery between patients who received THA or TKA in the NCP (n = 1066) versus the SOC (n = 504) within the study timeframe and had 12-month followup [1]. These results have been reported elsewhere [1, 9] and the focus of this article is on the collection of health resource use for costing over the continuum of care.

We measured health resource use to estimate the costs for surgical patients enrolled in the Alberta HKRP 12 months before and 12 months postsurgery. Resource use was summarized and categorized into four time components over the continuum of care (Table 1): (1) 12 months before surgery; (2) inpatient (including operating room, inpatient, and subacute care); (3) acute recovery—inpatient discharge to 3 months postsurgery; and (4) long-term recovery—3 months postsurgery to 12 months postsurgery.

Table 1.

Sources of resource use information for the Alberta Hip and Knee Replacement Project by time component in the continuum of care

Resource use variable Data source
12 months before survey (presurgery)
General practitioner visits MSK Alberta Health and Wellness physician claims database
Orthopaedic consults MSK
Other specialist MSK consults
Anesthesiology consults (< 90 days presurgery)
Internal medicine consults (< 90 days presurgery)
Cardiology consults (< 90 days presurgery)
Emergency room visits
Alternative healthcare provider visits Baseline patient questionnaire
Inpatient, operating room, and subacute care
OR anesthesiology MSK Alberta Health and Wellness physicians claims database
OR orthopedic surgeon MSK
Emergency room visits
Inpatient orthopaedic consults MSK
Inpatient internal medicine consults
Inpatient cardiology consults
Inpatient other specialist MSK consults
OR surgical assistants Hospital chart
Acute recovery (3 months postsurgery)
Homecare visits Regional Health Authorities database
Community physiotherapy visits
General practitioner visits MSK Alberta Health and Wellness physician claims database
Orthopaedic consults MSK
Other specialist MSK consults
Alternative healthcare provider visits 3-month followup patient questionnaire
Long-term recovery (3–12 months postsurgery)
Homecare visits Regional Health Authorities database
Community physiotherapy visits
General practitioner visits MSK Alberta Health and Wellness physician claims database
Orthopaedic consults MSK
Other specialist MSK consults
Alternative healthcare provider visits 12-month followup patient questionnaire

MSK codes = musculoskeletal diseases and MSK genetic disease codes; alternative healthcare visits = visits from physiotherapists, chiropractors, registered massage therapists, acupuncturist, and herbalists; OR = operating room.

A key principal in economic evaluation is to measure and summarize healthcare resource use separately from the valuation of the resources used [7]. We derived health resource use on an individual patient level during the study period from multiple sources to capture the full range of elements through the continuum of care for both the SOC and NCP. The data sources included administrative data from Alberta Health and Wellness (AHW) (eg, professional visits), the RHAs (eg, homecare and community physiotherapy), and hospital chart review (eg, surgical blood transfusions). Estimates of resource use that were not captured in AHW and RHA administrative health databases or hospital charts were collected through patient questionnaires administered at the time of randomization and 3 months and 1 year postsurgery (eg, use of a physiotherapist, chiropractor, and massage therapist) (Table 1). The key point to note is that some of these variables such as alternative care provider visits are not routinely collected in administrative databases but were included with the expectation that they may be important for resource use and costing purposes [13].

The next step in estimating costs was to obtain unit costs for each healthcare resource use item. Each regional hospital was responsible for the unit costs for acute care of all study patients and the new clinical pathway clinics. Historically, there was no standardized approach for costing each element for the inpatient TKA or THA procedure in Alberta. Consequently, it was challenging to compare across institutions or regions within a healthcare jurisdiction. A standardized approach had to be established for the evaluation of the new clinical pathway, whereby key financial experts from within the three participating regional health authorities, along with other costing experts, worked together using their respective historical administrative data to construct a standardized costing model for the hospital and regional health authority costs for THA and TKA procedures. The Alberta Standard Costing Model included costs from preoperative hospitalization visits to patient discharge from acute and subacute care. A listing of cost components was developed and agreed to by each of the three RHAs involved. Using historical data, each region provided cost averages, which were then weighted based on each regional health authority’s patient population to develop a provincial standardized costing model. These cost averages were used to calculate key performance indicators such as acute care cost and the cost of surgical versus nonsurgical cases.

The costing approaches differed somewhat among the three RHAs; two used internal models that were specific to the region and one used manual costing. For example, in Calgary, a costing system was developed based on the activities reflecting a typical patient and the costs associated with those activities. Where there were differences in the costing procedure, a proxy value was used. As an illustration, the anesthesiology technician and respiratory therapist were included in operating room costs in Edmonton, but not in Calgary; in this case, the additional cost for these positions was added to Calgary operating room costs to make them comparable to Edmonton.

In the HKRP, unit costs were obtained from the following sources: (1) AHW costs included all physician professional costs associated with patient consultations and performing medical procedures as well as nonphysician costs (eg, dietician visits, surgical assistants). The unit costs were obtained from the physician claims billing information based on the Alberta Fee Schedule for Medical Services; (2) RHA costs included nonphysician direct costs, including health professional salaries in the intervention clinic and the hospitals, clinic and hospital supplies and consumables, and indirect costs associated with outpatient clinics; acute care (hospital); subacute care; homecare; and community physiotherapy costs. This information was obtained from administrative data obtained from RHAs; and (3) patient costs included direct and indirect costs incurred by patients, including time off work; travel for physician visits and surgery; medication costs for the treatment of their hip or knee condition; and alternative care (eg, massage therapy). The associated resource use estimates were collected in the patient questionnaires at the time of consent for the period 1 year before surgery and 3 months and 12 months postsurgery. Costs for time off work for employed patients were estimated from the numbers of days off work and occupation code reported in the patient questionnaire and multiplied by the hourly compensation for each occupation as reported by Alberta Wage Statistics from the Alberta Wage and Salary Survey [10]. The cost for time lost from work was not calculated for retirees, homemakers, or students. For each patient, we estimated travel distances to the physician and hospital using postal codes and an electronic travel distance tool. A unit cost of 47.5 cents per kilometer was applied, consistent with the Government of Canada 2007 Travel Reimbursement Guidelines [6] to estimate the total travel cost.

Once the measurement framework and general approach to costing were decided, the first consideration in costing was to determine the range of costs to be included in the analysis [7]. Three key questions inform this decision: (1) the viewpoint of the analysis; (2) the relative order of magnitude of the costs; and (3) the time horizon over which costs are considered. Common viewpoints included in the evaluation of healthcare programs include those of the healthcare payer, the patient, and society. In the Alberta HKRP, data were collected to allow analysis from multiple viewpoints (Table 2): (1) healthcare payer: includes costs paid by the healthcare system: (a) Alberta Health and Wellness: all physician professional costs that occurred with patient consultations and performing medical procedures. These included professional costs from orthopaedic surgeons, general practitioners, and other physician specialists; (b) RHAs: the nonphysician health professional fees in the intervention clinic and the hospitals, clinic and hospital materials, and indirect costs associated with the outpatient clinics, acute care (hospital), subacute care, homecare, and community physiotherapy costs; (2) patient: includes all direct and indirect costs incurred by the patients. This may include time off work, travel time to and from physician visits and surgery, medication costs for the treatment of their hip or knee condition, and alternative care (eg, massage therapy).

Table 2.

Resource use by payer perspective for Alberta Hip and Knee Replacement Project

Perspective 12 months presurgery Inpatient (including OR and subacute) Postsurgical recovery (3 months and 3–12 months postsurgery)
Health Care Payer General practitioner visits (MSK diagnoses) Operating room anesthesiology Orthopaedic consults (MSK diagnoses)
Alberta Health and Wellness Orthopaedic consults (MSK diagnoses)
Other specialist (MSK diagnoses)
Anesthesiology consults (< 90 days presurgery)
Internal medicine consults (< 90 days presurgery)
Cardiology consults (< 90 days presurgery)
Operating room orthopaedic surgeon
Operating room surgical assist
General practitioner visits (MSK diagnoses)
Other specialist (MSK diagnoses)
Health Care Payer Preadmission clinic (control only): presurgery clinic administration cost Operating room nurses Community physiotherapy
Regional Health Authorities Intervention clinic visits
Pre-lab
Nursing, physiotherapy, clerical, and supplies
Blood collection (phlebotomy)
Prediagnostic images
Operating room technical support
Operating room drugs
Rehab compensation
Inpatient nurses
Blood transfusions
Inpatient laboratory testing
Inpatient respiratory therapy
Inpatient ECG/ECHO
Inpatient drugs
Inpatient meals
Inpatient linen
Inpatient equipment
Prosthesis
Cement cost
Inpatient other supplies
Inpatient other direct and indirect costs
Transport to subacute
Transport to another region
LOS subacute
Homecare
Adverse event readmissions
Patient Travel to all clinic visits
Analgesic medication cost
Time off work
Alternative health provider visits
Travel to hospital
Time off work
Analgesic medication cost
Time off work
Alternative health provider visits
Travel to all clinic visits
Travel for readmission

MSK codes = musculoskeletal diseases and MSK genetic disease codes; OR = operating room; ECG = electrocardiogram; ECHO = ultrasound; LOS = length of hospital stay.

There were two main steps to costing; each individual item was measured in terms of the quantity of resources that is consumed and then valued by assigning a cost to each unit of resource consumed [5]. The calculation of costs required both resource use and unit cost (or price). The quantity of resource use for each item is then multiplied by the relevant unit cost to obtain the total cost [7]. We summarized the distributions of continuous variables with means and percentages of total costs for each component of care by viewpoint.

Results

To inform estimates of the value of hip and knee arthroplasty across the continuum of care in the Alberta HKRP, multiple data sources were required for costs. This included the Alberta provincial Health and Wellness administrative data sets for physician medical services, the RHA administrative databases for nonphysician health professionals, and self-reported questionnaires for direct and indirect patient costs.

The viewpoint of the analysis had a substantial effect on the results in the Alberta HKRP (Table 3). Using the payer viewpoint, the cost to RHAs was close to 60% of the mean total cost ($14,342 of $24,422). From a patient perspective, the costs were considerable: time off work, travel to the clinic and hospital for preoperative and postoperative visits, medication costs, and costs associated with visits to alternative healthcare providers had a mean total cost of $7363, or 30% of the total cost over the continuum of care. Close to 80% of the costs borne by the patient occurred in the 12-month postsurgical time component. Although only 30% of the patients were employed; 75% of the total estimated costs were associated with time off work. This underscores the negative impact on work productivity up to 12 months postsurgery and will be a larger factor for those who have joints replaced during their active work years.

Table 3.

Estimated costs by viewpoint and component in the continuum of care

Component of care RHA mean cost ($) AHW mean cost ($) Mean total cost ($) (payer and patient) and percent of total Patient mean cost ($) Mean total cost ($) (payer and patient) and percent of total
Presurgery $1085 $465 $1550 (9%) $1489 $3040 (12%)
Inpatient* $12,958 $1800 $14,758 (87%) $67 $14,825 (61%)
3 months postsurgery $299 $105 $404 (2%) $3359 $3763 (15%)
3–12 months postsurgery $348 $348 (2%) $2447 $2795 (12%)
Mean total cost $14,342 $2718 $17,060 $7362 $24,422
Percent of total 59% 11% 30% 100%

* Inpatient cost included prosthesis without cement cost and subacute care; homecare and community physiotherapy costs were not collected for 3- to 12-month followup; AHW = Alberta Health and Wellness; RHA = Regional Health Authorities.

The distribution of costs among the four components of the continuum of care revealed that a substantive proportion of the total costs were incurred outside of acute care (Table 3). Although much attention tends to be focused on the acute care costs (hospital stay and surgery), the inpatient component was approximately 60% of the total cost. The remaining 40% of costs occurred in the context of the continuum of care 12 months presurgery and 12 months postsurgery.

Discussion

In the context of measuring the value of clinical pathways for TJA, costs should be considered across the full continuum of care, from patient referral to an orthopaedic surgeon through surgery, recovery, and rehabilitation. Furthermore, according to our earlier article based on the Alberta Hip and Knee Replacement Project, we determined healthcare resource use over the continuum of care 12 months before and 12 months postsurgery to examine the proportion of costs borne by the different public payers, at different stages along the continuum, and by the payer versus patient viewpoint.

Readers should be aware of the limitations of our study. First, we considered only two specific clinical pathways associated with THA and TKA that were compared in the Alberta HKRP. Consequently, the specific findings with respect to costs relate to these particular pathways implemented in the Alberta context. However, the general conclusions about the importance of capturing costs across the continuum of care and considering costs from multiple viewpoints are relevant outside of this setting. Second, in a publicly funded healthcare system such as that in Alberta, Canada, it is not typical for health resource use to be tracked in detail. When considering the costs to include in an evaluation, the focus needs to be on key cost drivers, particularly those that are expected to differ between the interventions being compared. For example, in the Alberta HKRP, it was anticipated that a key cost driver would be hospital length of stay. The average inpatient cost per diem for the HKRP was $1793 (excluding the prosthesis, operative procedure day, and subacute care). Consequently, an increase in hospital length of stay by 1 day would increase the total mean cost of the replacement by approximately 7% ($1793 of $24,422). Because the mean length of stay in the NCP was 4.7 days compared with 6.0 days in the SOC, the mean cost of an inpatient care component differed by more than $2000 between the NCP and the SOC. Third, it is typical for healthcare resource use and costs to be skewed because of a few complicated cases with high costs [14]. In examining costs along the continuum of care, it is important to differentiate between variability in resource use that occurs because of uncontrollable patient variables that result in variable patient outcomes, but are nonetheless predictable, and systematic variability resulting from differences in practice patterns of care. For example, in the Alberta HKRP, we observed enormous variability in total costs for the cohort—ranging from a minimum of just under $8000 to a maximum of over $180,000—mostly as a consequence of extended hospital stays up to 26 days. However, if we focus on systematic variability resulting from differences in practice patterns between the SOC and NCP, we can identify numerous possible opportunities to reduce inefficiencies and waste in the delivery of care. Although the minimum and maximum length of stay (uncontrollable patient variability) for the SOC and NCP were the same (minimum of 2.0 days and maximum of 26.0 days), the mean length of stay for the SOC was 6.0 days and 4.7 days for the NCP. The unadjusted mean inpatient care costs were consequently reduced for the NCP; however, this cost reduction was offset by an increase in pre- and postsurgical costs attributable mainly to rehabilitation visits, resulting in no difference in the overall mean cost between the SOC and NCP clinical pathways ($24,124 versus $24,492, respectively). This would suggest that although the implementation of a standardized clinical pathway can reduce length of stay, it may not result in a cost reduction overall. Fourth, we used a followup time of 12 months. The time horizon over which costs are considered should be long enough to capture all the meaningful differences in costs and outcomes between the intervention and comparators [7]. It is unnecessary to extend the time horizon beyond the period when there are no meaningful differences such as when the costs and outcomes of alternatives converge, but at the same time, horizon should be applied to costs and outcomes for analytical consistency. National guidelines for economic evaluation suggest a lifetime time horizon as a default, particularly for chronic conditions such as osteoarthritis [4].

We have illustrated some of the key principals for the economic evaluation of surgical orthopaedic interventions using the Alberta HKRP as an example. Ideally, all elements of the care process would be tracked, but this is not always practical in a public health system given the diverse array of elements in the care process and the complex system of care delivery. We used a predefined measurement framework that attempts to identify the common elements in the care delivery pathway and consistently measure costs and outcomes using common metrics over the continuum of care [12]. Published methodological guidelines for economic evaluation state that all relevant costs, calculated from healthcare resource use, should be considered in the analysis [7, 8]. Consequently, in the HKRP, we captured healthcare resource use 12 months before and 12 months postsurgery, because an important aspect of the NCP was the optimization of patients before surgery and rehabilitation after surgery. We derived health resource use during the study period from multiple sources to capture the full range of elements through the continuum of care for both the SOC and NCP.

By summarizing resource use into four components over the continuum of care using the measurement framework, it was revealed that 12-month postsurgery costs were a substantial component of total costs. This pattern is consistent with the Canadian case-control study of knee surgery reported by Hawker et al. [11]. Inpatient costs are the largest component of total care costs (61% and 68% in our study and Hawker et al.’s study, respectively) with pre- and postsurgical costs making up the remainder. However, Hawker et al. did not include the cost of services paid by patients and used a time period of 6 to 12 months for the postsurgical component of care. A literature review by Bozic et al. confirmed that most hip arthroplasty studies (62%) only consider costs during the initial acute care hospitalization or rehabilitation stay [3].

Furthermore, by examining costs from multiple viewpoints, the substantial burden to patients in terms of time away from work and out-of-pocket costs becomes apparent. In our HKRP study, patient costs were 30% of mean total costs over the continuum of care, 80% of which were incurred after the acute inpatient stay. To fully understand the costs and benefits of an intervention such as THA and TKA, a broader perspective than one limited to the payer should be considered because of this avoidable burden to patients. Nonetheless, the review by Bozic et al. [3] found that only a minority (17%) of economic evaluations considered costs beyond those incurred by the payer.

Finally, for surgical orthopaedic interventions, in which revisions are an important factor affecting outcomes and costs, it is appropriate to consider modeling as a complementary approach to extrapolate beyond the short timeframes typical of surgical trials. From a long-term perspective, it is relevant to consider the benefits and costs of alternative prosthetic technologies and their expected survival and arthroplasty requirements. Thus, although some prostheses are considerably more expensive compared with others as a one-time equipment cost, if we consider the long-term time horizon, and their potential to avoid revision surgery, they may be better value for money depending on the age of the patient receiving the arthroplasty. In this situation, it is necessary to use modeling as a complementary approach to extrapolate beyond the 12-month time horizon of the Alberta HKRP trial or have long-term registry data. Building databases through registries is a key strategy to informing such models.

We suggest future efforts to measure the value of surgical orthopaedic interventions should focus on developing sustainable improvement beyond the acute surgical component and over the continuum of care. Measures should include relevant outcomes and costs considering the viewpoint of the analysis, the key cost drivers and sources of variability, and the implications of the time horizon for analysis.

Acknowledgments

Project partners were Alberta Health Services-Calgary Health Region, Capital Health Authority, and David Thompson Health Region, Alberta Orthopaedic Society, and Alberta Health and Wellness. Participating orthopaedic surgeons were Greg Abelseth, Lance Bredo, Brian Burkart, John Cinats, Kelly deSouza, Hugh Dougall, Thomas Greidanus, Kenneth James, D. W. C. (Bill) Johnston, Guy Lavoie, James Mackenzie, Ed Masson, James McMillan, Stephen Miller, Gregory O’Connor, Timothy Pierce, Rod Reikie, Lowell Van Zuiden, Donald Weber, and Jason Werle. The Safety Review Committee consisted of John Donaghy, Joe Dort, Sr, and Troy Pederson. We especially thank the patients for their time and contributions to this study.

Footnotes

The Alberta Hip and Knee Replacement Pilot Project received ethical approval from the University of Calgary Ethics Review Board (Study ID 17951), the University of Alberta Ethics Review Board (Study ID 5660), and the College of Physicians and Surgeons of Alberta Ethics Review Board (Study ID REC-1376). Unrestricted grants were received from McCaig Institute for Bone & Joint Health (CF), Alberta Health and Wellness (CF), Max Bell Foundation (CF), and Norlien Foundation (CF).

Each author certifies that his or her institution approved the human protocol for this investigation, that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained.

All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research editors and board members are on file with the publication and can be viewed on request.

This work was performed at the University of Calgary, Calgary, Alberta, Canada.

References

  • 1.Alberta Health and Wellness. Alberta Hip and Knee Replacement Project Evaluation Report. Edmonton, Alberta: Alberta Health and Wellness; 2006.
  • 2.Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833–1840. [PubMed] [Google Scholar]
  • 3.Bozic KJ, Saleh KJ, Rosenberg AG, Rubash HE. Economic evaluation in total hip arthroplasty: analysis and review of the literature. J Arthroplasty. 2004;19:180–189. doi: 10.1016/S0883-5403(03)00456-X. [DOI] [PubMed] [Google Scholar]
  • 4.Guidelines for the Economic Evaluation of Health Technologies. CanadaOttawa: Canadian Agency for Drugs and Technologies in Health; 2006. [Google Scholar]
  • 5.A Guidance Document for the Costing Process. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1996. [Google Scholar]
  • 6.Canadian Institutes of Health Research. CIHR Travel Expenses Reimbursement Guidelines; 2007. Available at: www.cihr-irsc.gc.ca/e/35135.html. Accessed December 13, 2010.
  • 7.Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3. Oxford, UK: Oxford University Press; 2005. [Google Scholar]
  • 8.Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996. [Google Scholar]
  • 9.Gooch KL, Smith D, Wasylak T, Faris PD, Marshall DA, Kong H, Hibbert JE, Parker RD, Zernicke RF, Beaupre L, Pearce T, Johnston DW, Frank CB. The Alberta Hip and Knee Replacement Project: a model for health technology assessment based on comparative effectiveness of clinical pathways. Int J Technol Assess Health Care. 2009;25:113–123. doi: 10.1017/S0266462309090163. [DOI] [PubMed] [Google Scholar]
  • 10.Government of Alberta. Alberta WAGEinfo. Available at: http://alis.alberta.ca/wageinfo. Accessed December 13, 2010.
  • 11.Hawker GA, Badley EM, Croxford R, Coyte PC, Glazier RH, Guan J, Harvey BJ, Williams JI, Wright JG. A population-based nested case-control study of the costs of hip and knee replacement surgery. Med Care. 2009;47:732–741. doi: 10.1097/MLR.0b013e3181934553. [DOI] [PubMed] [Google Scholar]
  • 12.Health Quality Council of Alberta. Alberta Quality Maxrix for Health. Alberta: Health Quality Council of Alberta; 2004.
  • 13.Heiner DE, Mauerhan DR, Masonis JL, Heath J. Patient out-of-pocket expenses in major orthopedic procedures: total hip arthroplasty as a case study. J Arthroplasty. 2008;23:509–514. doi: 10.1016/j.arth.2007.05.029. [DOI] [PubMed] [Google Scholar]
  • 14.Willan AR, Briggs AH. Statistical Analysis of Cost-effectiveness Data. Oxford, UK: John Wiley & Sons Ltd; 2006. [Google Scholar]

Articles from Clinical Orthopaedics and Related Research are provided here courtesy of The Association of Bone and Joint Surgeons

RESOURCES